# Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/

## Facts

| Field | Value |
| --- | --- |
| Author Names | B.J. Monk,Maria Pilar Barretina-Ginesta,Bhavana Pothuri,Ignace Vergote,Whitney A. Spannuth Graybill,Mansoor Raza Mirza,C. C. McCormick,Domenica Lorusso,Richard G. Moore,Gilles Freyer,Roisin E. O’Cearbhaill,Florian Heitz,David M. O’Malley,Andrés Redondo,Mark S. Shahin,Christof Vulsteke,William H. Bradley,Charlotte Aaquist Haslund,Dana M. Chase,Carmela Pisano,L.L. Holman,M.J. Rubio Pérez,Paul DiSilvestro,Lydia Gaba,Thomas J. Herzog,Ilan Bruchim,Natalie Compton,L. Shtessel,Izabela A. Malinowska,Antonio González-Martı́n |
| Citations | 166 |
| DOI | 10.1016/j.annonc.2024.08.2241 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.annalsofoncology.org/article/S0923-7534(24)03762-1/pdf |
| OpenAlex ID | https://openalex.org/W4402541228 |
| PMID | 39284381 |
| Type | article |
| Year | 2024 |

## Paper authors

- [David M. O’Malley](https://scholariq.org/researchers/david-m-o-malley/)
- [Roisin E. O’Cearbhaill](https://scholariq.org/researchers/roisin-e-o-cearbhaill/)
- [Mansoor Raza Mirza](https://scholariq.org/researchers/mansoor-raza-mirza/)
- [Ignace Vergote](https://scholariq.org/researchers/ignace-vergote/)
- [Domenica Lorusso](https://scholariq.org/researchers/domenica-lorusso/)
- [Antonio González-Martı́n](https://scholariq.org/researchers/antonio-gonzalez-mart-n/)

## Paper funders

Showing 8 of 15.

- [Amgen](https://scholariq.org/funders/amgen/)
- [Bristol-Myers Squibb](https://scholariq.org/funders/bristol-myers-squibb/)
- [Pfizer](https://scholariq.org/funders/pfizer/)
- [AstraZeneca](https://scholariq.org/funders/astrazeneca/)
- [Celgene](https://scholariq.org/funders/celgene/)
- [Regeneron Pharmaceuticals](https://scholariq.org/funders/regeneron-pharmaceuticals/)
- [Clovis Oncology](https://scholariq.org/funders/clovis-oncology/)
- [Incyte](https://scholariq.org/funders/incyte/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Paper topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.